^
    Back
    Association details:
    Biomarker:NCOA4-RET fusion
    Cancer:Thyroid Gland Carcinoma
    Drug:Gavreto (pralsetinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2020
    Title:

    Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors

    Published date:
    05/13/2020
    Excerpt:
    Case study: 66-year-old man with poorly differentiated thyroid cancer… NCOA4-RET fusion; no previous treatments… Deep and durable PR with pralsetinib (18 months duration; 94% shrinkage of target lesions)